Best Vitelliform Macular Dystrophy, Retinitis Pigmentosa
Conditions
Brief summary
The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy. The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene. As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to: 1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s). 2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD. 3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment 4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.
Interventions
Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
Sponsors
Universität Tübingen
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
National Eye Institute (NEI)
Columbia University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Ability to provide informed consent * Diagnosis of BEST1-associated VMD by study physician, who are trained retinal specialists in the university clinic Must be able to commit to 4 follow-up study visits (3 years)
Exclusion criteria
* Systemic condition that prevents the participant from undergoing the exams
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantitative Fundus Autofluorescence (qAF) | Up to 3 years | — |
| Near-infrared fundus autofluorescence (NIR-AF) | Up to 3 years | — |
| Medmont Dark Adapted Chromatic (DAC) Automated Perimeter | Up to 3 years | — |
| Full-field electroretinogram (ERG) | Up to 3 years | ERG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol. |
| Electroocoulogram (EOG) | Up to 3 years | EOG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol |
| Optical Coherence Tomography (OCT) | Up to 3 years | — |
| Fundus Autofluorescence (FAF) | Up to 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Full-field Stimulus Testing | Up to 3 years |
| Best-corrected Visual Acuity (BCVA) | Up to 3 years |
| Color Fundus Photos | Up to 3 years |
| Macular Integrity Assessment (MAIA) Microperimetry | Up to 3 years |
| Goldman Kinetic Visual Field | Up to 3 years |
| Light-adapted Static Perimetry | Up to 3 years |
| Dark-adapted Chromatic Perimetry | Up to 3 years |
Countries
France, Germany, United States
Contacts
Primary ContactStephen H Tsang, MD, PhD
Outcome results
None listed